| Does pravastatin therapy affect cardiac enzyme levels after percutaneous coronary intervention? | |
| | |
MedLine Citation:
|
PMID: 17660157 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Serum cardiac enzyme elevation after percutaneous coronary intervention (PCI), a relatively common complication, is a prognostic determinant of long-term outcome in patients who undergo these procedures. Statins are postulated to reduce such complications. This study investigated the short-term effects of pravastatin on serum creatine kinase myocardial isoform (CK-MB) and serum cardiac troponin I (cTpI) levels after elective PCI. Of 93 patients studied, 72 (77.4%) were men, and 21 (22.6%) were women (mean age, 58.9+/-11.0 y). Patients were randomly divided into 3 groups before they underwent elective PCI. Preoperatively, group 1 patients (n=30) received pravastatin 10 mg/d, and group 2 patients (n=29) received pravastatin 40 mg/d. Control group patients (n=34) received no lipid-lowering medication. Serum CK-MB and serum cTpI levels were measured preoperatively and then again at 6, 24, and 36 h postoperatively. Demographic features of patients and characteristics of the PCI procedure, including number of vessels/lesions and duration and number of inflations, did not differ among groups (P>.05). Mean serum CK-MB and serum cTpI levels were significantly increased after PCI in all patients (P<.001). When compared with control group patients, those given pravastatin did not experience significantly lowered postprocedural serum CK-MB or serum cTpI levels (P>.05). Preprocedural pravastatin therapy at dosages of 10 mg/d and 40 mg/d seems inadequate for preventing serum cardiac enzyme elevations during short-term follow-up after PCI. Additional research on this topic is recommended. |
| | |
Authors:
|
Huseyin Bozbas; Aylin Yildirir; Serdar Mermer; Didem Konas; Ilyas Atar; Alp Aydinalp; Bulent Ozin; Mehmet E Korkmaz; Haldun Muderrisoglu |
Related Documents
:
|
18280057 - Observations on real-time prostate gland motion using electromagnetic tracking. 7261317 - Case report: changes in creatine kinase isoenzymes after myocardial infarction in a pat... 19562347 - The f/t-psa ratio in diagnosis of in-patients and out-patients: a unitary cutoff value ... 6613687 - Serum creatine kinase isoenzymes in patients with advanced malignant disease. 21641747 - The 12-lead electrocardiogram in patients with subarachnoid hemorrhage: early risk prog... 1247937 - Binocular visual field in strabismus. |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Advances in therapy Volume: 24 ISSN: 0741-238X ISO Abbreviation: Adv Ther Publication Date: 2007 May-Jun |
Date Detail:
|
Created Date: 2007-07-30 Completed Date: 2007-09-19 Revised Date: 2007-09-28 |
Medline Journal Info:
|
Nlm Unique ID: 8611864 Medline TA: Adv Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 493-504 Citation Subset: T |
Affiliation:
|
Department of Cardiology, Faculty of Medicine, Baskent University, Ankara, Turkey. hbozbas@gmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Analysis of Variance Angioplasty, Transluminal, Percutaneous Coronary* / adverse effects Cardiomyopathies / enzymology, etiology, prevention & control Creatine Kinase, MB Form / blood*, drug effects Female Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*, therapeutic use Male Middle Aged Pravastatin / pharmacology*, therapeutic use Premedication* Troponin I / blood*, drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Troponin I; 81093-37-0/Pravastatin; EC 2.7.3.2/Creatine Kinase, MB Form |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hemostatic effects of microporous polysaccharide hemosphere in a rat model with severe femoral arter...
Next Document: Fatal lactic acidosis and hypoglycemia in a patient with relapsed natural killer/T-cell lymphoma.